Suboptimal usage of proton pump inhibitors common

June 11, 2014
Suboptimal usage of proton pump inhibitors common

(HealthDay)—For patients with gastroesophageal reflux disease (GERD), those who receive a proton pump inhibitor (PPI) prescription from gastroenterologists are more likely to be optimal users and have better symptom control, according to a study published in the June issue of the American Journal of Gastroenterology.

Imran Sheikh, M.D., from Case Western Reserve University in Cleveland, and colleagues surveyed 1,959 patients with GERD at five clinics to assess dosing patterns and symptom control in over-the-counter (OTC) and prescription PPI users. Participants were surveyed regarding GERD diagnosis, use of PPIs, information on dosing, demographics, and Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).

The researchers found that 31 percent of participants used PPIs for GERD. Of these, 32 percent purchased OTC PPIs, while 31 and 37 percent, respectively, received prescriptions from gastroenterologists and . Optimal use was reported by 71 percent of those prescribed PPIs by gastroenterologists, compared with 47 percent of those receiving prescriptions from primary care providers and 39 percent of consumers (both P < 0.001). Patients prescribed PPIs by gastroenterologists had significant better GSAS symptom, frequency, and severity scores (all P < 0.001, compared with provider and consumer). Patients using PPIs optimally had significantly better GSAS symptom, frequency, and severity scores, compared with those taking PPIs suboptimally or excessively (all parameters, P < 0.001).

"Patients receiving prescription PPI from a gastroenterologist are more likely to be optimal users with better symptom control," the authors write.

Explore further: DDW: Gastroenterologists missing chances to shift to generic meds

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

DDW: Gastroenterologists missing chances to shift to generic meds

May 7, 2014
(HealthDay)—Although most gastroenterologists feel that store-brand and branded treatments are equivalent, most continue to recommend branded products for gastroesophageal reflux disease (GERD) and chronic constipation, ...

Many patients keep using PPIs after negative GERD test

June 5, 2012
(HealthDay) -- Nearly half of patients continue to use proton pump inhibitors (PPIs) even after pH studies confirm that they do not have gastroesophageal reflux disease (GERD), and most do not recall being instructed to stop ...

Prescription problems for vets on reflux drug

February 20, 2013
U.S. veterans diagnosed with gastroesophageal reflux disease (GERD) are frequently prescribed doses of proton pump inhibitors (PPIs), such as omeprazole (commonly known by brand names such as Prilosec), that are much higher ...

Widely used heartburn and peptic ulcer medicines increase risk of rare kidney disease

March 24, 2014
(Medical Xpress)—New Zealanders taking a proton pump inhibitor (PPI), a type of medicine used to treat gastric acid reflux disorders and peptic ulcer disease, are at an increased risk of a rare kidney disease, according ...

Heartburn controlled with step down to once daily therapy

February 27, 2012
(HealthDay) -- The majority of gastroesophageal reflux disease (GERD) patients who take twice-daily proton pump inhibitor (PPI) therapy, are able to successfully step down to management of heartburn with a daily dose of dexlansoprazole ...

Acid-suppressing medications associated with vitamin B12 deficiency

December 10, 2013
Use for 2 or more years of proton pump inhibitors and histamine 2 receptor antagonists (two types of acid-inhibiting medications) was associated with a subsequent new diagnosis of vitamin B12 deficiency, according to a study ...

Recommended for you

Finish your antibiotics course? Maybe not, experts say

July 27, 2017
British disease experts on Thursday suggested doing away with the "incorrect" advice to always finish a course of antibiotics, saying the approach was fuelling the spread of drug resistance.

Co-infection with two common gut pathogens worsens malnutrition in mice

July 27, 2017
Two gut pathogens commonly found in malnourished children combine to worsen malnutrition and impair growth in laboratory mice, according to new research published in PLOS Pathogens.

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.